NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (407)	2/13/1999 2:52:00 PM
From: Arthur Radley	Read Replies (1) of 613

Rick, your EXPERT opinion is needed. I have a position in ATRX, and their major technology is a drug delivery system called ATRIGEL. It is a biodegradable polymeric system that works by the body's own moist environment turning the delivered drug into a site specific timed released implant. They currently have FDA approval for ATRIDOX for treatment in the periodontal disease area in which the ATRIGEL system is the delivery system. My question to you relates to their planned human trials with their ATRIGEL system in the treatment of prostate cancer. They plan to deliver leuprolide acetate as a site specific drug in a 30 day delivery time-frame. How effective is leuprolide acetate? What I've been able to determine is that it is a $1.5 billion dollar drug and I wonder if such a delivery system by ATRX would enhance its performance as a cancer fighter. As always, thanks for your input. Cary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next